Andrew Hindman
Director/Board Member at BIOTIE THERAPIES CORP
Net worth: 3 M $ as of 31/03/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Deepa Pakianathan | M | 59 | 4 years | |
| Antero Kallio | M | 64 | 19 years | |
| Brett Grimaud | M | 50 | 3 years | |
| Ronald Cohen | M | 68 | 8 years | |
| Jane Wasman | F | 67 | 8 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Gregg Alton | M | 58 | 20 years | |
| Brett Pletcher | M | 56 | 17 years | |
| Mark Perry | M | 68 | 10 years | |
| Robert Morales | M | 57 | 7 years | |
| Linda Fitzpatrick | F | 67 | 10 years | |
| Brett K. Haumann | M | 54 | 7 years | |
| Adrian L. Rabinowicz | M | - | 6 years | |
| Andrew Cheng | M | 57 | 19 years | |
| Craig S. Gibbs | M | 61 |
Tobira Therapeutics, Inc. /Old/
 Tobira Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which focuses on developing and commercializing of therapies to treat liver disease, HIV, fibrosis and inflammation. Its lead product candidate, cenicriviroc or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. The company was founded by Eckard Weber in September 2006 and is headquartered in South San Francisco, CA. | 3 years |
| Catherine D. Strader | M | 70 | 4 years | |
| Susan Molineaux | M | 70 | 7 years | |
| Gail B. Cohen | F | - | 2 years | |
| Robert Gunderson | M | 72 | 8 years | |
| Bradford J. Shafer | M | 63 | 7 years | |
| Ian Smith | M | 58 | 12 years | |
| Helen Jenkins | F | 60 |
Tobira Therapeutics, Inc. /Old/
Tobira Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which focuses on developing and commercializing of therapies to treat liver disease, HIV, fibrosis and inflammation. Its lead product candidate, cenicriviroc or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. The company was founded by Eckard Weber in September 2006 and is headquartered in South San Francisco, CA. | - |
| Nicholas G. Moore | M | 82 | - | |
| Peter S. Ringrose | M | 78 | 7 years | |
| Carla A. Hills | F | 90 | - | |
| Asif Ali | M | 50 | 4 years | |
| Paul A. Berg | M | 97 | 13 years | |
| John Francis Cogan | M | 76 | - | |
| Dana Pizzuti | M | 69 | 11 years | |
| Gayle Edlund Wilson | F | 81 | - | |
| John Madigan | M | 86 | 12 years | |
| George M. Whitesides | M | 84 | 8 years | |
| Jeff Enejosa | M | - |
Tobira Therapeutics, Inc. /Old/
Tobira Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which focuses on developing and commercializing of therapies to treat liver disease, HIV, fibrosis and inflammation. Its lead product candidate, cenicriviroc or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. The company was founded by Eckard Weber in September 2006 and is headquartered in South San Francisco, CA. | - |
| Jung Choi | F | 54 | 8 years | |
| Martine Kraus | M | - |
Tobira Therapeutics, Inc. /Old/
Tobira Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which focuses on developing and commercializing of therapies to treat liver disease, HIV, fibrosis and inflammation. Its lead product candidate, cenicriviroc or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. The company was founded by Eckard Weber in September 2006 and is headquartered in South San Francisco, CA. | - |
| Andrew Aristidou | M | - | - | |
| Stephen Cheng | M | - | 7 years | |
| Robert Janssen | M | 70 | 2 years | |
| Shane Ward | M | 49 | 3 years | |
| Katie L. Watson | F | - | 16 years | |
| Jeffrey Hessekiel | M | 55 | 10 years | |
| Peter Virsik | M | - | 5 years | |
| John Begley | M | - | - | |
| Noreen Henig | M | 59 | 6 years | |
| Erik Emerson | M | 53 | 3 years | |
| Tse Li Yang | F | 51 | 12 years | |
| Eric Lefebvre | M | 60 |
Tobira Therapeutics, Inc. /Old/
Tobira Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which focuses on developing and commercializing of therapies to treat liver disease, HIV, fibrosis and inflammation. Its lead product candidate, cenicriviroc or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. The company was founded by Eckard Weber in September 2006 and is headquartered in South San Francisco, CA. | - |
| Elizabeth Ann Fagan | M | 74 | 2 years | |
| Elvia Cowan | F | 51 | 3 years | |
| Lian Hong Xu | M | 58 | 20 years | |
| Christopher Kenney | M | - | 3 years | |
| Lee Song | F | 49 | 14 years | |
| Sharon Barbari | F | 70 | 4 years | |
| Kitty Yale | F | 52 | 17 years | |
| Sung Lee | M | 53 | 14 years | |
| Carla Fiankan | F | - | 7 years | |
| Peter Carbone | M | - | - | |
| David Johnson | M | 55 | 15 years | |
| Holly Kramen | F | - | 1 years | |
| Elizabeth Bhatt | F | 56 | 11 years | |
| Brian P. Kearney | M | 52 | 21 years | |
| Maria Fardis | M | 56 | 11 years | |
| Caroline Dorsa | F | 64 | 1 years | |
| Jennifer Burstein | F | 52 | 9 years | |
| Caroline Loewy | F | 58 |
Tobira Therapeutics, Inc. /Old/
Tobira Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which focuses on developing and commercializing of therapies to treat liver disease, HIV, fibrosis and inflammation. Its lead product candidate, cenicriviroc or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. The company was founded by Eckard Weber in September 2006 and is headquartered in South San Francisco, CA. | 2 years |
| Karl G. Trass | M | 64 | - | |
| Richard Batycky | M | 56 | - | |
| Mark D. Matteucci | M | 70 | 11 years | |
| Kenneth Cundy | M | 65 | 8 years | |
| Michael W. Aguiar | M | 57 | - | |
| Alan Montgomery | M | 70 | 5 years | |
| Kevin B. Young | M | 66 | 10 years | |
| Antoun Nabhan | M | 49 |
Tobira Therapeutics, Inc. /Old/
Tobira Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which focuses on developing and commercializing of therapies to treat liver disease, HIV, fibrosis and inflammation. Its lead product candidate, cenicriviroc or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. The company was founded by Eckard Weber in September 2006 and is headquartered in South San Francisco, CA. | - |
| J. William Freytag | M | 72 | 1 years | |
| Robert L. Simon | M | 79 | 1 years | |
| Nicole Onetto | M | 71 | 1 years | |
| Gregory Critchfield | M | 72 |
Nodality, Inc.
 Nodality, Inc. BiotechnologyHealth Technology Nodality, Inc. develops bioinformatics tools to enhance drug development process. Its technology profiles signaling networks in single cells by multiparametric phospho-flow cytometry. The company was founded by Michael C. Needels, Omar D. Perez, Garry P. Nolan and Rodney Weldon Turner in 2003 and is headquartered in San Francisco, CA. | 6 years |
| Jeff Bird | M | 63 | 12 years | |
| Rebecca Coleman | M | - | 5 years | |
| Kathleen A. McGowan | F | 63 |
Tobira Therapeutics, Inc. /Old/
Tobira Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which focuses on developing and commercializing of therapies to treat liver disease, HIV, fibrosis and inflammation. Its lead product candidate, cenicriviroc or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. The company was founded by Eckard Weber in September 2006 and is headquartered in South San Francisco, CA. | 4 years |
| Kristen M. Metza | F | 64 | - | |
| Melissa Yeager | F | - | 8 years | |
| Enrique Carrazana | M | 62 | 5 years | |
| Howard Rosen | M | 66 | 4 years | |
| Phillip Gutry | M | 50 | 5 years | |
| Stephan Reynier | M | 55 | 4 years | |
| Brenda P. Fielding | F | - | 1 years | |
| Mark Sullivan | M | - | 2 years | |
| Christopher Griffith | M | 47 | 5 years | |
| Soon H. Lee | M | - | - | |
| Michael Hongjie Lan | M | 56 | - | |
| Gabriel Fox | M | - | 4 years | |
| Martin Freed | M | 63 | 1 years | |
| Carol Brosgart | M | 72 | 11 years | |
| Steven Pfeiffer | M | 48 | 4 years | |
| James Sapirstein | M | 63 | 2 years | |
| Kirk A. Christoffersen | M | 56 | 4 years | |
| Steven Fife | M | 65 | 1 years | |
| Paul Carter | M | 63 | 10 years | |
| Benedict Osorio | M | 67 | 2 years | |
| Aaron Brinkworth | M | - | 22 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 97 | 97.00% |
| Finland | 3 | 3.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Andrew Hindman
- Personal Network